Bone mineral content in patients with carcinoma of the prostate.
This study investigated the effect of metastatic prostatic carcinoma on bone density. Thirty patients underwent a lumbar spine scan with a dual photon absorptiometer. Of these patients, 9 had proven skeletal metastatic deposits in the area being investigated. Comparison of results with a non-matched control population with proven benign prostatic histology showed a significantly elevated linear bone mineral content (BMC) in the disease group. Patients scanned after a 3- or 6-month period of hormonal therapy demonstrated a rise in BMC values, although the trend was not statistically significant. Indices of calcium metabolism have also been investigated.
Mobb
G E
GE
Department of Urology, Royal United Hospital, Bath.
Moisey
C U
CU
Ring
E F
EF
D000135:Acid Phosphatase / Q000097:blood; D000368:Aged; D000369:Aged, 80 and over; D000469:Alkaline Phosphatase / Q000097:blood; D001859:Bone Neoplasms / Q000378:metabolism / Q000556:secondary*; D001842:Bone and Bones / Q000032:analysis*; D002118:Calcium / Q000378:metabolism; D003534:Cyproterone / Q000627:therapeutic use; D004054:Diethylstilbestrol / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008875:Middle Aged; D008903:Minerals / Q000032:analysis*; D011471:Prostatic Neoplasms / Q000378:metabolism*
D008903:Minerals; D004054:Diethylstilbestrol; D003534:Cyproterone; D000469:Alkaline Phosphatase; D000135:Acid Phosphatase; D002118:Calcium